Form 4: Hologic Director Martin Madaus Acquires Shares and Stock Options

Director Martin Madaus acquired restricted stock units and stock options in Hologic Inc.

Summary

• Director Martin Madaus acquired 342 restricted stock units of Hologic Inc. on December 9, 2024.
• These restricted stock units will vest on the date of the 2025 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis.
• Madaus also acquired non-qualified stock options for 1,016 shares of common stock at an exercise price of $75.79.
• These options become exercisable on the date of the 2025 Annual Meeting of Stockholders and expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction by a company director, which is generally a positive sign of confidence in the company. However, it is not a major event that would significantly impact sentiment.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future performance.
• The vesting of restricted stock units and exercisability of options at the 2025 Annual Meeting of Stockholders aligns the director's interests with those of the shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have made transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The acquisition of stock options and restricted stock units is a common form of compensation for directors and executives in publicly traded companies.
• The vesting and exercisability terms are typical, aligning with standard practices for equity-based compensation.

Stakeholder Impact

• The acquisition of shares and options by a director may be viewed positively by shareholders, indicating confidence in the company's future.

Next Steps

• The restricted stock units will vest at the 2025 Annual Meeting of Stockholders.
• The stock options will become exercisable at the 2025 Annual Meeting of Stockholders.

Key Dates

Keywords

Hologic, Director, Stock Options, Restricted Stock Units, Insider Trading, Equity Compensation, Form 4